Gilead’s Acquisition of Arcellx Valued at up to $7.8 Billion Completes

Gilead, best known for its HIV and liver disease treatments, has been diversifying its revenue streams amid declining sales of its COVID-19 drug Veklury and the impending loss of patent protection for key therapies. The acquisition of Arcellx aligns with Gilead’s broader strategy to strengthen its position in oncology, particularly in the rapidly evolving field of CAR-T cell therapy. Arcellx’s anito-cel, a novel CAR-T therapy for multiple myeloma, is a key focus of the deal. The U.S. Food and Drug Administration (FDA) is currently reviewing anito-cel as a fourth-line treatment, with a decision expected by December 2026.

The $7.8 billion deal includes upfront payments and potential milestone-based payments. Gilead will pay Arcellx shareholders $115 per share in cash, with an additional $5 per share CVR tied to sales performance. The transaction also removes up to $1.5 billion in potential milestone payments from Gilead’s financial obligations. Analysts note that the deal could be accretive to Gilead’s earnings per share starting in 2028, assuming FDA approval of anito-cel. The acquisition is structured to consolidate Gilead’s control over anito-cel, which it co-developed with Arcellx through its Kite Pharma subsidiary.

Anito-cel, developed by Arcellx and Kite Pharma, targets multiple myeloma using a novel approach involving a binding domain engineered to enhance efficacy. This contrasts with existing CAR-T therapies like Carvykti (developed by Johnson & Johnson and Legend Biotech), which generated $1.9 billion in sales in 2025. Analysts, including RBC Capital Markets’ Brian Abrahams, have highlighted anito-cel’s potential for a better safety profile compared to current CAR-T treatments. The FDA’s review of anito-cel is critical, as approval would solidify Gilead’s position in the competitive CAR-T market.

Gilead’s move into oncology has been a key growth driver. The company’s 2017 acquisition of Kite Pharma for $12 billion provided access to groundbreaking therapies like Yescarta and Tecartus, which generated over $1 billion annually in 2025. However, Gilead’s cell therapy unit faced challenges in 2025, with sales declining 7% due to manufacturing complexities and competition in institutionally administered treatments. The Arcellx acquisition is seen as a strategic step to bolster Gilead’s oncology pipeline and mitigate risks associated with patent expirations.

The deal is notable as the first major oncology acquisition of 2026, surpassing Genmab’s $8 billion acquisition of Merus in 2025. Industry observers suggest the transaction reflects growing confidence in CAR-T therapy despite hurdles such as high costs and complex administration. The acquisition may also influence biotech M&A trends, as pharmaceutical companies seek to secure early-stage innovations ahead of regulatory milestones.

The transaction requires approval from regulatory bodies, including the FDA for anito-cel’s approval and antitrust reviews. Gilead’s integration of Arcellx’s technologies, including early-stage treatments for acute myeloid leukemia and generalized myasthenia gravis, will be critical to realizing the deal’s long-term value. Analysts caution that Gilead’s existing debt levels may raise questions about its balance sheet flexibility, particularly if the FDA’s approval for anito-cel is delayed.

Gilead’s acquisition of Arcellx represents a significant bet on the future of CAR-T therapy and its potential to transform the treatment of multiple myeloma. The deal underscores the pharmaceutical industry’s focus on oncology innovation amid shifting market dynamics and regulatory landscapes. As the FDA’s decision on anito-cel approaches, the success of this acquisition will hinge on both the therapy’s approval and Gilead’s ability to integrate and scale Arcellx’s pipeline effectively.